Literature DB >> 6721990

Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite.

G W Mihaly, S A Ward, G Edwards, M L Orme, A M Breckenridge.   

Abstract

A method is described for the simultaneous determination of the carboxylic acid and N-acetyl-derivatives of primaquine, in plasma and urine. After oral administration of 45 mg primaquine, to five healthy volunteers, absorption was rapid, with peak primaquine levels of 153.3 +/- 23.5 ng/ml at 3 +/- 1 h, followed by an elimination half-life of 7.1 +/- 1.6 h, systemic clearance of 21.1 +/- 7.1 l/h, volume of distribution of 205 +/- 371 and cumulative urinary excretion of 1.3 +/- 0.9% of the dose. Primaquine underwent rapid conversion to the carboxylic acid metabolite of primaquine, which achieved peak levels of 1427 +/- 307 ng/ml at 7 +/- 4 h. Levels of this metabolite were sustained in excess of 1000 ng/ml for the 24 h study period, and no carboxyprimaquine was recovered in urine. N-acetyl primaquine was not detected in plasma or urine. Following [14C]-primaquine administration to one subject, plasma radioactivity levels rapidly exceeded primaquine concentrations. Plasma radioactivity was accounted for mainly as carboxyprimaquine . Though 64% of the dose was recovered over 143 h, as [14C]-radioactivity in urine, only 3.6% was due to primaquine. As neither carboxyprimaquine nor N- acetylprimaquine were detected in urine, the remaining radioactivity was due to unidentified metabolites.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6721990      PMCID: PMC1463409          DOI: 10.1111/j.1365-2125.1984.tb02369.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Determination of primaquine in biological fluids by reversed-phase high-performance liquid chromatography.

Authors:  S A Ward; G Edwards; M L Orme; A M Breckenridge
Journal:  J Chromatogr       Date:  1984-01-13

2.  The search for new antimalarial drugs.

Authors:  R E Strube
Journal:  J Trop Med Hyg       Date:  1975-08

3.  Microbial metabolism studies on the major microbial and mammalian metabolite of primaquine.

Authors:  C D Hufford; A M Clark; I N Quinones; J K Baker; J D McChesney
Journal:  J Pharm Sci       Date:  1983-01       Impact factor: 3.534

4.  Naphthoxylactic acid after single and long-term doses of propranolol.

Authors:  T Walle; E C Conradi; U K Walle; T C Fagan; T E Gaffney
Journal:  Clin Pharmacol Ther       Date:  1979-11       Impact factor: 6.875

5.  Metabolism of 8-aminoquinoline antimalarial agents.

Authors:  A Strother; I M Fraser; R Allahyari; B E Tilton
Journal:  Bull World Health Organ       Date:  1981       Impact factor: 9.408

6.  High-performance liquid chromatographic analysis of the metabolism of primaquine and the identification of a new mammalian metabolite.

Authors:  J K Baker; J D McChesney; C D Hufford; A M Clark
Journal:  J Chromatogr       Date:  1982-06-11

7.  Plasma kinetics and urinary excretion of primaquine in man.

Authors:  J Greaves; D A Evans; H M Gilles; K A Fletcher; D Bunnag; T Harinasuta
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

  7 in total
  63 in total

1.  Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue.

Authors:  Sophie H Adjalley; Geoffrey L Johnston; Tao Li; Richard T Eastman; Eric H Ekland; Abraham G Eappen; Adam Richman; B Kim Lee Sim; Marcus C S Lee; Stephen L Hoffman; David A Fidock
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-31       Impact factor: 11.205

Review 2.  Antimalarial pharmacokinetics and treatment regimens.

Authors:  N J White
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

3.  Pharmacokinetics of mefloquine in the presence of primaquine.

Authors:  J Karbwang; K Na Bangchang; A Thanavibul; D J Back; D Bunnag
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

4.  Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects?

Authors:  Bui Tri Cuong; Vu Quoc Binh; Bui Dai; Dinh Ngoc Duy; Claire M Lovell; Karl H Rieckmann; Michael D Edstein
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

5.  Selective toxicity of the antimalarial primaquine-evidence for both uncoupling and inhibitory effects of a metabolite on the energetics of mitochondria and its ATP synthase complex.

Authors:  J K Baker; J M Hullihen; P L Pedersen
Journal:  Pharm Res       Date:  1986-10       Impact factor: 4.200

Review 6.  8-Aminoquinoline Therapy for Latent Malaria.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2019-07-31       Impact factor: 26.132

7.  Lymphocyte proliferative response and subset profiles during extended periods of chloroquine or primaquine prophylaxis.

Authors:  D J Fryauff; A L Richards; J K Baird; T L Richie; E Mouzin; E Tjitra; M A Sutamihardja; S Ratiwayanto; H Hadiputranto; R P Larasati; N Pudjoprawoto; B Subianto; S L Hoffman
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

Review 8.  Clinical pharmacokinetics of antimalarial drugs.

Authors:  N J White
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

9.  HIV treatments have malaria gametocyte killing and transmission blocking activity.

Authors:  Charlotte V Hobbs; Takeshi Q Tanaka; Olga Muratova; Jillian Van Vliet; William Borkowsky; Kim C Williamson; Patrick E Duffy
Journal:  J Infect Dis       Date:  2013-03-28       Impact factor: 5.226

10.  Differential CYP 2D6 metabolism alters primaquine pharmacokinetics.

Authors:  Brittney M J Potter; Lisa H Xie; Chau Vuong; Jing Zhang; Ping Zhang; Dehui Duan; Thu-Lan T Luong; H M T Bandara Herath; N P Dhammika Nanayakkara; Babu L Tekwani; Larry A Walker; Christina K Nolan; Richard J Sciotti; Victor E Zottig; Philip L Smith; Robert M Paris; Lisa T Read; Qigui Li; Brandon S Pybus; Jason C Sousa; Gregory A Reichard; Sean R Marcsisin
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.